Sign in
Not yet recruitingNo phase

Construction and Validation of a Clinical Cohort on the Pathogenesis Evolution and Syndrome-Differentiated Treatment of Chronic Obstructive Pulmonary Disease Based on Core Targets of Airway Inflammation and Remodeling

Key facts

Who runs it
First Affiliated Hospital of Ningbo University
Where
China4 sites in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
People taking part
360 people, planned
Starts
15 Dec 2026
Expected to end
1 May 2030
Type of study
Interventional, 15 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Yuping Yifei herbal formula
  • standardized Western medical treatment
  • Liujun Fuzheng herbal formula
  • Qiyi Peitu herbal formula
  • Shenqi Naqi herbal formula
  • Fufei Gushen herbal formula
  • Shengmai Runyuan herbal formula
  • Qinbei Qingfei herbal formula
  • Erchen Shunqi herbal formula
  • Banlou Kuanxiong herbal formula
Record updated
18 November 2026

Who can take part

Age
40 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 34 criteriaShow less

Who can take part

  • COPD diagnosed on clinical grounds and post-bronchodilator FEV1/FVC <0.70
  • Age 40 years or older, any sex
  • Clinically stable during the 4 weeks before enrollment, without a COPD exacerbation or initiation/change of systemic antibiotics or systemic glucocorticoids for worsening respiratory symptoms
  • Predominant TCM syndrome of lung qi deficiency, lung-spleen qi deficiency, lung-kidney qi deficiency, or lung-kidney qi-yin deficiency, according to the 2011 TCM syndrome diagnostic criteria for COPD
  • Able to understand the study and provide written informed consent
  • Able to complete clinical assessments, sample collection, and follow-up
  • COPD diagnosed on clinical grounds and post-bronchodilator FEV1/FVC <0.70; current acute exacerbation assessed clinically
  • Age 40 years or older, any sex
  • Hospitalized for the current AECOPD episode, with screening and randomization completed within 24 hours after admission
  • Onset of acute worsening of respiratory symptoms no more than 5 days before enrollment
  • Cumulative systemic antibiotic and/or systemic glucocorticoid treatment for the current episode no more than 48 hours before enrollment
  • Predominant TCM syndrome of phlegm-heat obstructing the lung or phlegm-turbidity obstructing the lung, according to the 2011 TCM syndrome diagnostic criteria for COPD
  • Able to understand the study and provide written informed consent
  • Able to complete clinical assessments, sample collection, and follow-up

Who cannot take part

  • Systemic antibiotics or systemic glucocorticoids within 2 weeks before enrollment, or long-term systemic glucocorticoid maintenance therapy
  • Prior major pulmonary surgery, including lung volume reduction surgery or lung transplantation
  • Systemic antibiotics or systemic glucocorticoids for reasons other than the current exacerbation within 2 weeks, or long-term systemic glucocorticoid maintenance therapy
  • Prior major pulmonary surgery, including lung volume reduction surgery or lung transplantation
  • Active pulmonary tuberculosis, pulmonary embolism, lung tumor, or another clearly diagnosed respiratory disease
  • Severe cardiac, hepatic, renal, or hematologic disease, or psychiatric disease preventing cooperation
  • Allergy to study herbal components or a contraindication to herbal therapy
  • Blood transfusion within 4 weeks, participation in another interventional clinical study, or history of alcohol or drug abuse
  • Deterioration not attributable to AECOPD; active pulmonary tuberculosis, invasive fungal disease, or pulmonary infection requiring pathogen-specific treatment as judged by the investigator
  • Pulmonary embolism, lung tumor, or another clearly diagnosed respiratory disease
  • Severe cardiac, hepatic, renal, or hematologic disease, or psychiatric disease preventing cooperation
  • Allergy to study herbal components or a contraindication to herbal therapy
  • Blood transfusion within 4 weeks, participation in another interventional clinical study, or history of alcohol or drug abuse
  • TCM decoctions, patent medicines, or granules for COPD, cough, wheeze, or sputum within 2 weeks when judged likely to affect efficacy assessment
  • Pregnancy, breastfeeding, or planned pregnancy
  • Investigator judges participation unsuitable
  • TCM decoctions, patent medicines, or granules for COPD, cough, wheeze, or sputum within 2 weeks when judged likely to affect efficacy assessment
  • Immediate need for intensive care, invasive mechanical ventilation, altered consciousness, or hemodynamic instability at enrollment
  • Pregnancy, breastfeeding, or planned pregnancy
  • Investigator judges participation unsuitable

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This multicenter, randomized, open-label clinical trial will enroll 360 adults with chronic obstructive pulmonary disease (COPD): 240 with stable COPD and 120 hospitalized with an acute exacerbation (AECOPD). Participants will be stratified by disease stage and traditional Chinese medicine (TCM) syndrome. Within each syndrome stratum, they will be assigned to standardized Western medical treatment alone or the same treatment plus a syndrome-specific optimized herbal formula; selected strata will also include an innovative herbal formula group. Stable-phase participants will receive the study herbal treatment for 12 weeks, and AECOPD participants for 2 weeks. Both cohorts will be followed for 24 weeks. The study will assess lung function and exacerbations in stable COPD, and early dyspnea improvement and length of hospital stay in AECOPD. It will also assess symptoms, quality of life, TCM syndrome scores, safety, and biological markers.

The 15 groups in the trial

  • Stable COPD - Lung Qi Deficiency - Optimized Yuping Yifei FormulaTreatment being tested

    24 participants with stable COPD and lung qi deficiency receive the optimized Yuping Yifei herbal formula plus standardized Western medical treatment for 12 weeks.

    Treatment: Yuping Yifei herbal formula and standardized Western medical treatment

  • Stable COPD - Lung Qi Deficiency - Standard Western TreatmentExisting treatment, for comparison

    24 participants with stable COPD and lung qi deficiency receive standardized Western medical treatment without the study herbal formula.

    Treatment: standardized Western medical treatment

  • Stable COPD - Lung-Spleen Qi Deficiency - Optimized Liujun Fuzheng FormulaTreatment being tested

    24 participants with stable COPD and lung-spleen qi deficiency receive the optimized Liujun Fuzheng herbal formula plus standardized Western medical treatment for 12 weeks.

    Treatment: standardized Western medical treatment and Liujun Fuzheng herbal formula

  • Stable COPD - Lung-Spleen Qi Deficiency - Innovative Qiyi Peitu FormulaTreatment being tested

    24 participants with stable COPD and lung-spleen qi deficiency receive the innovative Qiyi Peitu herbal formula plus standardized Western medical treatment for 12 weeks.

    Treatment: standardized Western medical treatment and Qiyi Peitu herbal formula

  • Stable COPD - Lung-Spleen Qi Deficiency - Standard Western TreatmentExisting treatment, for comparison

    24 participants with stable COPD and lung-spleen qi deficiency receive standardized Western medical treatment without the study herbal formula.

    Treatment: standardized Western medical treatment

  • Stable COPD - Lung-Kidney Qi Deficiency - Optimized Shenqi Naqi FormulaTreatment being tested

    24 participants with stable COPD and lung-kidney qi deficiency receive the optimized Shenqi Naqi herbal formula plus standardized Western medical treatment for 12 weeks.

    Treatment: standardized Western medical treatment and Shenqi Naqi herbal formula

  • Stable COPD - Lung-Kidney Qi Deficiency - Innovative Fufei Gushen FormulaTreatment being tested

    24 participants with stable COPD and lung-kidney qi deficiency receive the innovative Fufei Gushen herbal formula plus standardized Western medical treatment for 12 weeks.

    Treatment: standardized Western medical treatment and Fufei Gushen herbal formula

  • Stable COPD - Lung-Kidney Qi Deficiency - Standard Western TreatmentExisting treatment, for comparison

    24 participants with stable COPD and lung-kidney qi deficiency receive standardized Western medical treatment without the study herbal formula.

    Treatment: standardized Western medical treatment

  • Stable COPD - Lung-Kidney Qi-Yin Deficiency - Optimized Shengmai Runyuan FormulaTreatment being tested

    24 participants with stable COPD and lung-kidney qi-yin deficiency receive the optimized Shengmai Runyuan herbal formula plus standardized Western medical treatment for 12 weeks.

    Treatment: standardized Western medical treatment and Shengmai Runyuan herbal formula

  • Stable COPD - Lung-Kidney Qi-Yin Deficiency - Standard Western TreatmentExisting treatment, for comparison

    24 participants with stable COPD and lung-kidney qi-yin deficiency receive standardized Western medical treatment without the study herbal formula.

    Treatment: standardized Western medical treatment

  • AECOPD - Phlegm-Heat Obstructing Lung - Optimized Qinbei Qingfei FormulaTreatment being tested

    24 hospitalized participants with AECOPD and phlegm-heat obstructing the lung receive the optimized Qinbei Qingfei herbal formula plus standardized Western medical treatment for 2 weeks.

    Treatment: standardized Western medical treatment and Qinbei Qingfei herbal formula

  • AECOPD - Phlegm-Heat Obstructing Lung - Standard Western TreatmentExisting treatment, for comparison

    24 hospitalized participants with AECOPD and phlegm-heat obstructing the lung receive standardized Western medical treatment without the study herbal formula.

    Treatment: standardized Western medical treatment

  • AECOPD - Phlegm-Turbidity Obstructing Lung - Optimized Erchen Shunqi FormulaTreatment being tested

    24 hospitalized participants with AECOPD and phlegm-turbidity obstructing the lung receive the optimized Erchen Shunqi herbal formula plus standardized Western medical treatment for 2 weeks.

    Treatment: standardized Western medical treatment and Erchen Shunqi herbal formula

  • AECOPD - Phlegm-Turbidity Obstructing Lung - Innovative Banlou Kuanxiong FormulaTreatment being tested

    24 hospitalized participants with AECOPD and phlegm-turbidity obstructing the lung receive the innovative Banlou Kuanxiong herbal formula plus standardized Western medical treatment for 2 weeks.

    Treatment: standardized Western medical treatment and Banlou Kuanxiong herbal formula

  • AECOPD - Phlegm-Turbidity Obstructing Lung - Standard Western TreatmentExisting treatment, for comparison

    24 hospitalized participants with AECOPD and phlegm-turbidity obstructing the lung receive standardized Western medical treatment without the study herbal formula.

    Treatment: standardized Western medical treatment

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
18 November 2026
Construction and Validation of a Clinical Cohort on the Pathogenesis Evolution and Syndrome-Differentiated Treatment of Chronic Obstructive Pulmonary Disease Based on Core Targets of Airway Inflammation and Remodeling (NCT07944157) – Frontlight Research